OBJECTIVE: This study was intended to present evidence for the reliability and validity of an Italian version of the MOS-HIV Health Survey and to identify important disease-related factors associated with health-related quality of life (HRQoL) in people with nonadvanced HIV. DESIGN: In this cross-sectional study, HRQoL was measured using an Italian version of the MOS-HIV Health Survey questionnaire in 213 HIV-infected people without previous opportunistic infections or neoplasms attending an outpatient clinic in a university hospital. Distribution of scores, reliability, and validity were calculated, and presence and frequency of HIV-related symptoms were recorded and transformed into a score. The relation of HRQoL values to sociodemographic, epidemiologic, and clinical data was assessed. RESULTS: The level of internal consistency of the Italian version of the MOS-HIV Health Survey was high (Cronbach's alpha, 0.80-0.93), and items demonstrated acceptable discrimination across scales. At linear regression analysis, all domains of HRQoL correlated with symptom score (r2 range, 0.07-0.41), but only the pain and physical-functioning scores showed a significant correlation with CD4 cell count. A weighted sum of single domains of HRQoL, TOTQoL, is also strongly correlated with symptom score (r2 = 0.57; p < .0001) but not with CD4 cell count (r2 = 0.01; p = .1). Using multivariate analysis, only symptom score (p < .0001) and total number of daily pills (p = .03) showed significant association with HRQoL. The same results were observed when analysis was performed only on people with CD4 levels <200/microl. CONCLUSIONS: This study presents the first evidence for the reliability and validity of a HRQoL instrument in Italian for people with HIV. Results also suggest a strong impact of symptoms on all measured dimensions of health status. The number of pills required to be taken daily is the only other significant factor associated with a lower HRQoL, whereas no relations were found with CD4 cell count or Karnofsky performance status values. To improve HRQoL in persons with nonadvanced HIV disease, symptom control could be a crucial element of medical treatment.
OBJECTIVE: This study was intended to present evidence for the reliability and validity of an Italian version of the MOS-HIV Health Survey and to identify important disease-related factors associated with health-related quality of life (HRQoL) in people with nonadvanced HIV. DESIGN: In this cross-sectional study, HRQoL was measured using an Italian version of the MOS-HIV Health Survey questionnaire in 213 HIV-infected people without previous opportunistic infections or neoplasms attending an outpatient clinic in a university hospital. Distribution of scores, reliability, and validity were calculated, and presence and frequency of HIV-related symptoms were recorded and transformed into a score. The relation of HRQoL values to sociodemographic, epidemiologic, and clinical data was assessed. RESULTS: The level of internal consistency of the Italian version of the MOS-HIV Health Survey was high (Cronbach's alpha, 0.80-0.93), and items demonstrated acceptable discrimination across scales. At linear regression analysis, all domains of HRQoL correlated with symptom score (r2 range, 0.07-0.41), but only the pain and physical-functioning scores showed a significant correlation with CD4 cell count. A weighted sum of single domains of HRQoL, TOTQoL, is also strongly correlated with symptom score (r2 = 0.57; p < .0001) but not with CD4 cell count (r2 = 0.01; p = .1). Using multivariate analysis, only symptom score (p < .0001) and total number of daily pills (p = .03) showed significant association with HRQoL. The same results were observed when analysis was performed only on people with CD4 levels <200/microl. CONCLUSIONS: This study presents the first evidence for the reliability and validity of a HRQoL instrument in Italian for people with HIV. Results also suggest a strong impact of symptoms on all measured dimensions of health status. The number of pills required to be taken daily is the only other significant factor associated with a lower HRQoL, whereas no relations were found with CD4 cell count or Karnofsky performance status values. To improve HRQoL in persons with nonadvanced HIV disease, symptom control could be a crucial element of medical treatment.
Authors: G Guaraldi; G Orlando; R Murri; M Vandelli; M De Paola; B Beghetto; G Nardini; S Ciaffi; F Vichi; A W Wu Journal: Qual Life Res Date: 2006-02 Impact factor: 4.147
Authors: Robert Burgoyne; Evan Collins; Cheryl Wagner; Susan Abbey; Mark Halman; Margaret Nur; Sharon Walmsley Journal: Qual Life Res Date: 2005-05 Impact factor: 4.147
Authors: Patrizia Schifano; Piero Borgia; Albert W Wu; Teresa Spadea; Giuseppe Milanese; Carlo A Perucci Journal: Qual Life Res Date: 2003-12 Impact factor: 4.147
Authors: R Bucciardini; R Murri; M Guarinieri; F Starace; M Martini; A Vatrella; L Cafaro; M Fantoni; R Grisetti; A d'Arminio Monforte; V Fragola; R Arcieri; C Del Borgo; A Tramarin; M Massella; D Lorenzetti; S Vella Journal: Qual Life Res Date: 2006-04 Impact factor: 4.147
Authors: Daniel J Skiest; Amy Krambrink; Zhaohui Su; Kevin R Robertson; David M Margolis Journal: J Acquir Immune Defic Syndr Date: 2008-12-01 Impact factor: 3.731
Authors: Panagiota G Stasinopoulou; Chara Tzavara; Christine Dimitrakaki; Ourania Georgiou; Ioannis G Baraboutis; Athanasios Skoutelis; Vassilios Papastamipoulos; Yannis Tountas Journal: Qual Life Res Date: 2010-03 Impact factor: 4.147
Authors: Giovanni Guaraldi; Rita Murri; Gabriella Orlando; Chiara Giovanardi; Nicola Squillace; Marcella Vandelli; Barbara Beghetto; Giulia Nardini; Maria De Paola; Roberto Esposito; Albert W Wu Journal: AIDS Patient Care STDS Date: 2008-07 Impact factor: 5.078